Haemonetics (Haemonetics) Debt-to-Equity

: 0.92 (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

Haemonetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $14 Mil. Haemonetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $857 Mil. Haemonetics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $943 Mil. Haemonetics's debt to equity for the quarter that ended in Dec. 2023 was 0.92.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Haemonetics's Debt-to-Equity or its related term are showing as below:

HAE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.33 Med: 0.56 Max: 1.16
Current: 0.92

During the past 13 years, the highest Debt-to-Equity Ratio of Haemonetics was 1.16. The lowest was 0.33. And the median was 0.56.

HAE's Debt-to-Equity is ranked worse than
86.68% of 713 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs HAE: 0.92

Haemonetics Debt-to-Equity Historical Data

The historical data trend for Haemonetics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.52

0.75

0.98

1.03

0.94

Haemonetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.99	0.94	0.89	0.85	0.92

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Haemonetics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haemonetics Debt-to-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Haemonetics's Debt-to-Equity falls into.

Haemonetics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Haemonetics's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.784	+	754.102)	/	817.997
	=	0.94

Haemonetics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(13.736	+	856.849)	/	943.319
	=	0.92

Haemonetics (NYSE:HAE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Haemonetics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Haemonetics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Haemonetics (Haemonetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

HAZ:Germany

Address

125 Summer Street, Boston, MA, USA, 02110

Website

https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Executives

Stewart W Strong	officer: President, Global Hospital	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni	officer: EVP, Chief Technology Officer	HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant	director	2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens	officer: EVP, Global Manufacturing	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil	officer: EVP and General Counsel	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell	officer: VP, Chief Accounting Officer	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin	officer: President, Global Plasma & BC	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller	officer: SVP, Human Resources	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll	director	PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein	officer: VP, Corporate Controller	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon,	director, officer: President & CEO	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca	officer: EVP, Chief Financial Officer	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr.	officer: EVP, Chief Financial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson	director	16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277